Onco Wiki / Bandera roja

CML high-risk by ELTS (EUTOS Long-Term Survival score) — favors 2nd-generation TKI (nilot...

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDRF-CML-HIGH-RISK-ELTS
TipoSeñal de alerta
Situaciónreviewed 2026-04-25 | pending_clinical_signoff
EnfermedadesDIS-CML
FuentesSRC-ELN-CML-2020 SRC-ESMO-CML-2017 SRC-NCCN-MPN-2025

Origen de la bandera roja

DefiniciónCML high-risk by ELTS (EUTOS Long-Term Survival score) — favors 2nd-generation TKI (nilotinib / dasatinib / bosutinib) over imatinib for faster deep molecular response and improved long-term outcomes
Dirección clínicaintensificar
Categoríahigh-risk-biology
Algoritmo de cambiosALGO-CML-1L

Lógica de activación

{
  "any_of": [
    {
      "finding": "cml_elts_risk",
      "value": "high"
    },
    {
      "finding": "cml_sokal_risk",
      "value": "high"
    },
    {
      "finding": "cml_eutos_risk",
      "value": "high"
    }
  ],
  "type": "risk_score"
}

Notas

ELN 2020 prefers ELTS over Sokal for predicting CML-related death and guiding 1L TKI selection in younger patients seeking treatment-free remission. High-risk patients gain more from 2nd-gen TKIs in early deep molecular response, but no consistent OS difference vs imatinib. Comorbidity profile (RF-CML-COMORBIDITY-COMPLEX) co-determines which 2nd-gen agent. STUB — requires clinical co-lead signoff.

Utilizado por

Algoritmos

Indicación

Señal de alerta